Security Snapshot

Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) Institutional Ownership

CUSIP: 29384C108

13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

112

Shares (Excl. Options)

24,428,065

Price

$10.28

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
TRDA on Nasdaq
Shares outstanding
38,346,880
Price per share
$12.62
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
24,428,065
Total reported value
$250,954,853
% of total 13F portfolios
0%
Share change
+473,511
Value change
+$6,142,652
Number of holders
112
Price from insider filings
$12.62
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 29384C108.
  • 112 institutions reported positions in Q4 2025.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 112 to 10 between Q4 2025 and Q1 2026.
  • Reported value moved from $250,954,853 to $234,647.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 112 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 29384C108?
CUSIP 29384C108 identifies TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
5AM Ventures V, L.P. 11% $25,485,387 4,123,849 Kush Parmar 14 Nov 2025
ROCHE FINANCE LTD 6.9% $23,019,270 2,569,115 Roche Finance Ltd 31 Dec 2024
BlackRock, Inc. 5.3% $17,691,090 1,974,452 BlackRock, Inc. 31 Dec 2024
TCG Crossover GP I, LLC 5% $11,849,186 1,917,344 TCG Crossover GP I, LLC 19 Nov 2025
JANUS HENDERSON GROUP PLC 4% -27% $9,964,391 -$3,932,443 1,521,281 -28% JANUS HENDERSON GROUP PLC 30 Jun 2025
PRICE T ROWE ASSOCIATES INC /MD/ 0.9% -84% $2,091,051 -$12,800,322 360,526 -86% T. Rowe Price Associates, Inc. 30 Sep 2025

As of 31 Dec 2025, 112 institutional investors reported holding 24,428,065 shares of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA). This represents 64% of the company’s total 38,346,880 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BAKER BROS. ADVISORS LP 13% 5,072,730 +4.3% 0.31% $52,147,664
5AM Venture Management, LLC 11% 4,056,379 -4.7% 13% $41,699,576
BlackRock, Inc. 5.6% 2,147,260 +5% 0% $22,073,833
TCG Crossover Management, LLC 5.4% 2,088,392 +257% 0.71% $21,468,670
VANGUARD GROUP INC 4.3% 1,632,460 +1.8% 0% $16,781,689
WELLINGTON MANAGEMENT GROUP LLP 2.7% 1,044,758 +9.5% 0% $10,740,113
StepStone Group LP 2% 761,277 0% 4.5% $7,825,928
GEODE CAPITAL MANAGEMENT, LLC 1.7% 639,947 -0.8% 0% $6,580,002
STATE STREET CORP 1.3% 508,789 +2% 0% $5,230,351
MILLENNIUM MANAGEMENT LLC 1.3% 497,695 -41% 0% $5,116,305
JACOBS LEVY EQUITY MANAGEMENT, INC 0.95% 362,786 +15% 0.01% $3,729,440
PRICE T ROWE ASSOCIATES INC /MD/ 0.85% 327,423 -9.2% 0% $3,367,000
ACADIAN ASSET MANAGEMENT LLC 0.81% 310,833 +4.3% 0.01% $3,193,000
CITADEL ADVISORS LLC 0.76% 292,770 -13% 0% $3,009,676
DIMENSIONAL FUND ADVISORS LP 0.71% 273,378 -31% 0% $2,809,666
MORGAN STANLEY 0.68% 260,251 -25% 0% $2,675,384
RENAISSANCE TECHNOLOGIES LLC 0.66% 252,635 -57% 0% $2,597,088
ROYCE & ASSOCIATES LP 0.64% 247,147 -28% 0.03% $2,540,671
NORTHERN TRUST CORP 0.59% 226,301 -11% 0% $2,326,375
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.58% 221,269 +19% 0% $2,274,645
GOLDMAN SACHS GROUP INC 0.54% 205,173 -7.7% 0% $2,109,181
BNP PARIBAS FINANCIAL MARKETS 0.47% 180,969 0% 0% $1,860,361
Qube Research & Technologies Ltd 0.46% 176,018 -39% 0% $1,809,465
Woodline Partners LP 0.37% 142,110 0.01% $1,460,891
ALGERT GLOBAL LLC 0.34% 128,611 -0.93% 0.02% $1,322,000

Institutional Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 18,592 $234,647 -$1,613 $12.62 10
2025 Q4 24,428,065 $250,954,853 +$6,142,652 $10.28 112
2025 Q3 28,408,651 $164,766,270 -$9,410,304 $5.80 114
2025 Q2 29,583,750 $198,790,015 -$4,881,409 $6.72 105
2025 Q1 30,241,830 $274,509,238 -$4,478,805 $9.04 110
2024 Q4 30,637,008 $529,755,566 +$9,629,460 $17.29 102
2024 Q3 30,099,996 $481,057,545 +$6,089,620 $15.98 97
2024 Q2 29,668,185 $422,803,373 +$52,052,901 $14.25 82
2024 Q1 26,027,444 $368,797,900 -$3,772,264 $14.17 76
2023 Q4 26,281,861 $396,641,035 +$3,492,844 $15.09 62
2023 Q3 26,035,608 $411,375,608 +$4,515,692 $15.80 55
2023 Q2 25,751,810 $389,877,766 +$13,317,282 $15.14 56
2023 Q1 24,900,040 $361,043,649 +$2,708,627 $14.50 53
2022 Q4 24,715,588 $334,178,958 +$2,434,963 $13.52 46
2022 Q3 24,517,008 $386,369,092 -$2,728,204 $15.76 33
2022 Q2 24,778,477 $301,833,417 -$12,927,920 $12.18 35
2022 Q1 25,876,494 $242,821,140 +$2,263,033 $9.39 48
2021 Q4 24,861,440 $425,110,000 +$413,748,000 $17.12 45